Welcome to the CI Agent Dashboard
Monitor competitive intelligence across multiple pharmaceutical companies. Use the client selector to switch between companies or enable cross-client comparison mode.
Merck Pharmaceuticals
Enterprise Plan • Last updated: May 20, 2025
24
Total Alerts
8
Pipeline Updates
12
Clinical Trial Changes
4
Regulatory Updates
Pfizer Inc.
Enterprise Plan • Last updated: May 20, 2025
31
Total Alerts
14
Pipeline Updates
9
Clinical Trial Changes
8
Regulatory Updates
Novartis AG
Enterprise Plan • Last updated: May 20, 2025
19
Total Alerts
6
Pipeline Updates
10
Clinical Trial Changes
3
Regulatory Updates
Johnson & Johnson
Enterprise Plan • Last updated: May 20, 2025
27
Total Alerts
11
Pipeline Updates
13
Clinical Trial Changes
3
Regulatory Updates
Cross-Client Comparison
Recent Alerts
FDA issues new guidance for immuno-oncology trial endpoints
Pfizer announces positive Phase 3 results for PF-06939926
Novartis receives FDA approval for Kesimpta in RMS
Merck's KEYTRUDA meets primary endpoint in KEYNOTE-598
Pipeline Tracker
Recent updates across all clients:
Pfizer's PF-06939926 - Phase 3 results
Duchenne muscular dystrophy | Gene therapy
Novartis's Kesimpta - FDA approval
Multiple Sclerosis | Anti-CD20 mAb
Merck's KEYTRUDA - KEYNOTE-598 results
NSCLC | PD-1 inhibitor
Weekly Snapshot
Latest Snapshot
May 17, 2025
Next Snapshot
May 24, 2025
Key highlights from the latest weekly snapshot:
- FDA issued new guidance for immuno-oncology trial endpoints
- Pfizer announced positive Phase 3 results for DMD gene therapy
- Novartis received FDA approval for Kesimpta in RMS
- Merck's KEYTRUDA met primary endpoint in KEYNOTE-598
Data Snacks
View All Data SnacksQuick insights from across all clients:
Immuno-Oncology Landscape
PD-1/PD-L1 inhibitors continue to dominate the immuno-oncology space, with 5 major players having approved products and 12+ in late-stage development.
Multiple Sclerosis Market Dynamics
The approval of Novartis's Kesimpta introduces a new self-administered anti-CD20 therapy, potentially disrupting the current treatment paradigm.
RSS Feed Integration
Manage RSS FeedsYour Feeder.co account is connected. 15 feeds are being synchronized.
Recent Feed Items
FDA Approves New Treatment for Multiple Sclerosis
FDA.gov • 3h ago
Pfizer Announces Positive Phase 3 Results
Pfizer.com • 5h ago
New Clinical Trial Data Presented at ASCO
ASCO.org • 1d ago
© 2025 CI Agent. All rights reserved.